Compare CCBG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCBG | ANNX |
|---|---|---|
| Founded | 1895 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.0M | 812.7M |
| IPO Year | 1994 | 2020 |
| Metric | CCBG | ANNX |
|---|---|---|
| Price | $51.83 | $5.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $50.00 | $16.50 |
| AVG Volume (30 Days) | 96.3K | ★ 4.7M |
| Earning Date | 04-20-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.17 | $16,320.74 |
| P/E Ratio | $55.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.02 | $2.03 |
| 52 Week High | $52.22 | $7.18 |
| Indicator | CCBG | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 44.36 |
| Support Level | $44.48 | $4.66 |
| Resistance Level | N/A | $5.65 |
| Average True Range (ATR) | 1.51 | 0.50 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 88.67 | 15.12 |
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.